NCT04060173 is a Phase 1 clinical trial of ABP-671 in Hyperuricemia, sponsored by Atom Therapeutics Co., Ltd.

Who is sponsoring NCT04060173?

NCT04060173 is sponsored by Atom Therapeutics Co., Ltd.

What drugs are being tested in NCT04060173?

Interventions in NCT04060173: ABP-671, Placebo.

What condition does NCT04060173 study?

NCT04060173 studies Hyperuricemia, Gout.

Is NCT04060173 still recruiting?

NCT04060173 is currently completed. Last updated 12 February 2020.

Last reviewed 2020-02-12 · How we verify

NCT04060173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

Completed Phase 1 Last updated 12 February 2020

What this trial tests

Phase 1 trial testing ABP-671 in Hyperuricemia in 27 participants. Completed in 7 February 2020.

Timeline

5 September 2019

Primary endpoint
29 December 2019

7 February 2020

Quick facts

Lead sponsor	Atom Therapeutics Co., Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	27
Start date	5 September 2019
Primary completion	29 December 2019
Estimated completion	7 February 2020
Sites	1 location across United States

Drugs / interventions tested

ABP-671 — full drug profile →
Placebo

Conditions studied

Hyperuricemia — all drugs for Hyperuricemia →
Gout — all drugs for Gout →

Sponsor

Atom Therapeutics Co., Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Hyperuricemia or Gout. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Review of Urate-Lowering Therapeutics: From the Past to the Future.
Jenkins C, Hwang JH, Kopp JB, Winkler CA, et al · · 2022 · cited 38× · PMID 36081938 · DOI 10.3389/fphar.2022.925219
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects.
Gurwith M, Wu RJ, Schwertschlag U, Jin AW, et al · · 2025 · PMID 41340907 · DOI 10.2147/dddt.s553918

Verify or expand the search:

Other trials of ABP-671

Trials testing the same drug.

NCT06276556 — Extension Study of ABP-671 in Participants With Gout · Phase 2, PHASE3 · terminated
NCT05818085 — Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout · Phase 2, PHASE3 · completed
NCT04638543 — A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia · Phase 2 · completed
NCT04303039 — Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects · Phase 1 · completed
NCT03906006 — A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Hyperuricemia

Currently open trials in the same condition.

NCT07144332 — This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Ord · recruiting
NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
NCT06859073 — A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia · Phase 1 · recruiting
NCT06463561 — CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea · Phase 4 · recruiting
NCT06729853 — PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function · Phase 1, PHASE2 · active not recruiting

Other Atom Therapeutics Co., Ltd trials

Trials by the same sponsor.

NCT07323095 — Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia · Phase 2 · not yet recruiting
NCT07367971 — Drug-Drug Interaction Study of ABP-671 in Gout Patients · Phase 1 · recruiting
NCT06276556 — Extension Study of ABP-671 in Participants With Gout · Phase 2, PHASE3 · terminated
NCT06258213 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers · Phase 1 · completed
NCT05818085 — Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04060173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atom Therapeutics Co., Ltd
Last refreshed: 12 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04060173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing